Marktprognose für Therapeutika gegen Infektionskrankheiten in Süd- und Mittelamerika bis 2030 – Regionale Analyse – nach Arzneimittelklasse (antiviral, antibakteriell, antimykotisch und andere), Indikation (HIV, Hepatitis, Tuberkulose, Grippe, HPV und andere), Verabreichungsweg (oral, parenteral, topisch und andere) und Vertriebskanal (Krankenhausapotheken, Einzelhandelsapotheken und andere)
Wachsende Chancen in Entwicklungsländern beflügeln den Markt für Therapeutika gegen Infektionskrankheiten in Süd- und Mittelamerika
Die zunehmende Zahl an Infektionskrankheiten wird voraussichtlich den Verkauf von Medikamenten gegen Infektionskrankheiten in Entwicklungsländern steigern. Darüber hinaus spielen hohe Investitionen in Gesundheitsforschung und Biowissenschaften in Schwellenländern eine Schlüsselrolle bei der Förderung der neuesten Technologien in Entwicklungsländern, was wiederum die Neigung zur Diagnose und Behandlung von Infektionskrankheiten unterstützt. So fordert UNAIDS Investitionen in Höhe von 29 Milliarden US-Dollar bis 2025, um den Bedarf der Länder mit niedrigem und mittlerem Einkommen im Rahmen der AIDS-Bekämpfung zu decken. Daher wird erwartet, dass sich den wichtigen Herstellern von Therapeutika für Infektionskrankheiten in den aufstrebenden Märkten für Therapeutika für Infektionskrankheiten in Brasilien in Zukunft lukrative Gelegenheiten bieten. Dies liegt an der hohen Verbreitung von Infektionskrankheiten wie Hepatitis, HAI, HIV und Grippe, der großen Patientenzahl, einem Anstieg des verfügbaren Einkommens der Bevölkerung, einer Verbesserung der Gesundheitsinfrastruktur und dem zunehmenden Medizintourismus in diesen Ländern.
Marktüberblick über Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika
Der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika ist in Brasilien, Argentinien und den Rest von Süd- und Mittelamerika unterteilt. Der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika wird voraussichtlich aufgrund der zunehmenden Verbreitung von Infektionskrankheiten, eines Anstiegs der Forschungsaktivitäten und der steigenden Gesundheitsausgaben der Länder in der Region wachsen. Brasilien hat aufgrund steigender Gesundheitsausgaben enorme Fortschritte im Gesundheitssektor gemacht. Laut der International Trade Administration gibt Brasilien ca. 9,1 % seines BIP für das Gesundheitswesen aus und ist der größte Gesundheitsmarkt in Lateinamerika. Der Markt für Therapeutika für Infektionskrankheiten in Brasilien wird aufgrund der zunehmenden Verbreitung von Infektionskrankheiten voraussichtlich boomen.
Infektionskrankheiten sind in Brasilien nach wie vor eine bedeutende Todesursache. Eine Umfrage ergab, dass bei Männern und Kindern unter 5 Jahren eine hohe Belastung durch Infektionskrankheiten beobachtet wurde, hauptsächlich aufgrund von HIV/AIDS. Laut den Daten des Gemeinsamen Programms der Vereinten Nationen für HIV/AIDS (UNAIDS) lebten im Jahr 2022 in Brasilien rund 990.000 Menschen mit HIV und AIDS. Aufgrund der oben genannten Faktoren wird daher erwartet, dass der Markt für Therapeutika für Infektionskrankheiten in Brasilien im Prognosezeitraum wachsen wird.
Umsatz und Prognose für den Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika bis 2030 (Mio. USD)
Marktsegmentierung für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika
Der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika ist nach Arzneimittelklasse, Indikation, Verabreichungsweg, Vertriebskanal und Land kategorisiert.
Basierend auf der Arzneimittelklasse ist der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika in antivirale, antibakterielle, antimykotische und andere Mittel unterteilt. Das antivirale Segment hatte 2022 den größten Marktanteil.
In Bezug auf die Indikation ist der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika in HIV, Hepatitis, Tuberkulose, Grippe, HPV und andere Mittel unterteilt. HIV hatte 2022 den größten Marktanteil.
Basierend auf der Verabreichungsart ist der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika in oral, parenteral, topisch und andere Mittel unterteilt. Das orale Segment hatte 2022 den größten Marktanteil.
In Bezug auf den Vertriebskanal ist der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika in Krankenhausapotheken, Einzelhandelsapotheken und andere Mittel unterteilt. Die Krankenhausapotheken hatten 2022 den größten Marktanteil.
Nach Ländern ist der Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika in Brasilien, Argentinien und den Rest von Süd- und Mittelamerika unterteilt. Brasilien dominierte 2022 den Marktanteil von Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc und Pfizer Inc sind einige der führenden Unternehmen auf dem Markt für Therapeutika für Infektionskrankheiten in Süd- und Mittelamerika.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 South & Central America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - South & Central America Market Analysis
5.1 South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. South & Central America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Infectious Disease Therapeutics Market - Country Analysis
10.1 South & Central America Infectious Disease Therapeutics Market
10.1.1 South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Brazil: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.2.2 Brazil: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.2.3 Brazil: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.2.4 Brazil: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.3 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.4 Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Argentina: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.4.2 Argentina: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.4.3 Argentina: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.4.4 Argentina: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.5 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.6 Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.6.2 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.6.3 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.6.4 Rest of South & Central America: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. South & Central America Infectious Disease Therapeutics Market Segmentation
Table 2. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Country
Table 7. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 20. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. South & Central America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. South & Central America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. South & Central America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. South & Central America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. South & Central America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: South & Central America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. South & Central America Infectious Disease Therapeutics Market, By Key Country - Revenue (2022) (US$ Million)
Figure 26. South & Central America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Brazil: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Argentina: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Rest of South & Central America: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc
7. Merck & Co Inc
8. Pfizer Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.